Suppr超能文献

甾醇 O-酰基转移酶 (SOAT/ACAT) 活性是在肝细胞脂滴中形成胆固醇晶体所必需的。

Sterol O-acyltransferase (SOAT/ACAT) activity is required to form cholesterol crystals in hepatocyte lipid droplets.

机构信息

Department of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Department of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Department of Physiology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.

出版信息

Biochim Biophys Acta Mol Cell Biol Lipids. 2024 Aug;1869(6):159512. doi: 10.1016/j.bbalip.2024.159512. Epub 2024 May 16.

Abstract

OBJECTIVE

Excess cholesterol storage can induce the formation of cholesterol crystals in hepatocyte lipid droplets. Such crystals distinguish metabolic dysfunction associated steatohepatitis (MASH) from simple steatosis and may underlie its pathogenesis by causing cell damage that triggers liver inflammation. The mechanism linking cholesterol excess to its crystallization in lipid droplets is unclear. As cholesteryl esters localize to and accumulate in lipid droplets more readily than unesterified free cholesterol, we investigated whether cholesterol esterification by sterol O-acyltransferase (SOAT), also known as acyl co-A cholesterol acyltransferase (ACAT), is required for hepatocyte lipid droplet crystal formation.

METHOD

Cholesterol crystals were measured in cholesterol loaded Hep3B hepatocytes, RAW264.7 macrophages, and mouse liver using polarizing light microscopy. We examined the effect of blocking SOAT activity on crystal formation and compared these results to features of cholesterol metabolism and the progression to intracellular crystal deposits.

RESULTS

Cholesterol loading of Hep3B cells caused robust levels of lipid droplet localized crystal formation in a dose- and time-dependent manner. Co-treatment with SOAT inhibitors and genetic ablation of SOAT1 blocked crystal formation. SOAT inhibitor also blocked crystal formation in low density lipoprotein (LDL) treated Hep3B cells, acetylated LDL treated RAW 264.7 macrophages, and in the liver of mice genetically predisposed to hepatic cholesterol overload and in mice with cholesterol enriched diet-induced MASH.

CONCLUSION

SOAT1-mediated esterification may underlie cholesterol crystals associated with MASH by concentrating it in lipid droplets. These findings imply that inhibiting hepatocyte SOAT1 may be able to alleviate cholesterol associated MASH. Moreover, that either a lipid droplet localized cholesteryl ester hydrolase is required for cholesterol crystal formation, or the crystals are composed of cholesteryl ester.

摘要

目的

过量胆固醇储存会导致肝细胞脂滴中胆固醇晶体的形成。这些晶体将代谢功能障碍相关脂肪性肝炎(MASH)与单纯性脂肪变性区分开来,并且可能通过引起触发肝脏炎症的细胞损伤来为其发病机制提供基础。胆固醇过量与其在脂滴中结晶的机制尚不清楚。由于胆固醇酯比未酯化的游离胆固醇更容易定位于脂滴并积累,因此我们研究了固醇 O-酰基转移酶(SOAT),也称为酰基辅酶 A 胆固醇酰基转移酶(ACAT),是否需要将胆固醇酯化来形成肝细胞脂滴晶体。

方法

使用偏光显微镜测量胆固醇负载的 Hep3B 肝细胞、RAW264.7 巨噬细胞和小鼠肝脏中的胆固醇晶体。我们研究了阻断 SOAT 活性对晶体形成的影响,并将这些结果与胆固醇代谢特征和向细胞内晶体沉积物的进展进行了比较。

结果

Hep3B 细胞的胆固醇负载以剂量和时间依赖的方式引起了大量的脂滴定位晶体形成。SOAT 抑制剂的共同处理和 SOAT1 的基因缺失阻断了晶体形成。SOAT 抑制剂还阻断了 LDL 处理的 Hep3B 细胞、乙酰化 LDL 处理的 RAW264.7 巨噬细胞以及遗传易患肝脏胆固醇过载的小鼠和富含胆固醇饮食诱导的 MASH 小鼠肝脏中的晶体形成。

结论

SOAT1 介导的酯化作用可能通过将其集中在脂滴中来解释与 MASH 相关的胆固醇晶体。这些发现意味着抑制肝细胞 SOAT1 可能能够缓解胆固醇相关的 MASH。此外,需要一种脂滴定位的胆固醇酯水解酶来形成胆固醇晶体,或者晶体由胆固醇酯组成。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验